CY1112971T1 - Σουλφοναμιδια 2-(υποκατεστημενο-αμινο)-βενζοθειαζολης ως αναστολεις της πρωτεασης ηiv - Google Patents

Σουλφοναμιδια 2-(υποκατεστημενο-αμινο)-βενζοθειαζολης ως αναστολεις της πρωτεασης ηiv

Info

Publication number
CY1112971T1
CY1112971T1 CY20121100429T CY121100429T CY1112971T1 CY 1112971 T1 CY1112971 T1 CY 1112971T1 CY 20121100429 T CY20121100429 T CY 20121100429T CY 121100429 T CY121100429 T CY 121100429T CY 1112971 T1 CY1112971 T1 CY 1112971T1
Authority
CY
Cyprus
Prior art keywords
amino
substituted
inhibitors
present
benzothiothiazole
Prior art date
Application number
CY20121100429T
Other languages
Greek (el)
English (en)
Inventor
Kock Herman De
Tim Hugo Maria Jonckers
Paul Jozef Gabriel Maria Boonants
Stefaan Julien Last
Inge Dierynck
Judith Eva Baumeister
Klooster Gerben Albert Eleutherius Van´T
Original Assignee
Tibotec Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharmaceuticals filed Critical Tibotec Pharmaceuticals
Publication of CY1112971T1 publication Critical patent/CY1112971T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CY20121100429T 2006-06-23 2012-05-08 Σουλφοναμιδια 2-(υποκατεστημενο-αμινο)-βενζοθειαζολης ως αναστολεις της πρωτεασης ηiv CY1112971T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06116003 2006-06-23
EP07765554A EP2035432B1 (en) 2006-06-23 2007-06-22 2-(Substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors

Publications (1)

Publication Number Publication Date
CY1112971T1 true CY1112971T1 (el) 2016-04-13

Family

ID=37596252

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100429T CY1112971T1 (el) 2006-06-23 2012-05-08 Σουλφοναμιδια 2-(υποκατεστημενο-αμινο)-βενζοθειαζολης ως αναστολεις της πρωτεασης ηiv

Country Status (31)

Country Link
US (1) US8202887B2 (US20060241273A1-20061026-C00026.png)
EP (1) EP2035432B1 (US20060241273A1-20061026-C00026.png)
JP (1) JP5232776B2 (US20060241273A1-20061026-C00026.png)
KR (1) KR101419320B1 (US20060241273A1-20061026-C00026.png)
CN (1) CN101479275B (US20060241273A1-20061026-C00026.png)
AP (1) AP2069A (US20060241273A1-20061026-C00026.png)
AR (1) AR061619A1 (US20060241273A1-20061026-C00026.png)
AT (1) ATE544769T1 (US20060241273A1-20061026-C00026.png)
AU (1) AU2007262943B2 (US20060241273A1-20061026-C00026.png)
BR (1) BRPI0713487B1 (US20060241273A1-20061026-C00026.png)
CA (1) CA2653233C (US20060241273A1-20061026-C00026.png)
CL (1) CL2007001826A1 (US20060241273A1-20061026-C00026.png)
CY (1) CY1112971T1 (US20060241273A1-20061026-C00026.png)
DK (1) DK2035432T3 (US20060241273A1-20061026-C00026.png)
EA (1) EA016387B1 (US20060241273A1-20061026-C00026.png)
ES (1) ES2381129T3 (US20060241273A1-20061026-C00026.png)
HK (1) HK1125633A1 (US20060241273A1-20061026-C00026.png)
IL (1) IL195381A (US20060241273A1-20061026-C00026.png)
JO (1) JO2841B1 (US20060241273A1-20061026-C00026.png)
MX (1) MX2009000160A (US20060241273A1-20061026-C00026.png)
MY (1) MY146805A (US20060241273A1-20061026-C00026.png)
NZ (1) NZ573286A (US20060241273A1-20061026-C00026.png)
PE (1) PE20080342A1 (US20060241273A1-20061026-C00026.png)
PL (1) PL2035432T3 (US20060241273A1-20061026-C00026.png)
PT (1) PT2035432E (US20060241273A1-20061026-C00026.png)
SI (1) SI2035432T1 (US20060241273A1-20061026-C00026.png)
TW (1) TWI415851B (US20060241273A1-20061026-C00026.png)
UA (1) UA96445C2 (US20060241273A1-20061026-C00026.png)
UY (1) UY30416A1 (US20060241273A1-20061026-C00026.png)
WO (1) WO2007147884A1 (US20060241273A1-20061026-C00026.png)
ZA (1) ZA200810350B (US20060241273A1-20061026-C00026.png)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3090B1 (ar) * 2009-12-11 2017-03-15 Janssen Sciences Ireland Uc 5- امينو-4- هيدروكسي-بنتويل اميدات
MX2012015293A (es) 2010-07-02 2013-05-30 Gilead Sciences Inc Derivados de acido 2-quinolinil-acetico como compuestos antivirales.
EP2588450B1 (en) 2010-07-02 2017-05-24 Gilead Sciences, Inc. Napht-2-ylacetic acid derivatives to treat aids
US9024038B2 (en) * 2010-12-27 2015-05-05 Purdue Research Foundation Compunds and methods for treating HIV
EP3181555B1 (en) * 2011-04-21 2018-11-28 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
US9096586B2 (en) 2012-04-20 2015-08-04 Gilead Sciences, Inc. Therapeutic compounds
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1370543T1 (sl) * 2001-02-14 2007-04-30 Tibotec Pharm Ltd Sirokospektralni 2-(substituirani-amino)-benzotiazol sulfonamidni inhibitorji HIV proteaze
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
KR20050025647A (ko) * 2002-08-02 2005-03-14 티보텍 파마슈티칼즈 리미티드 광범위 2-아미노-벤조티아졸 설폰아미드 hiv프로테아제 저해제
EP1670448B1 (en) * 2003-09-30 2007-11-21 Tibotec Pharmaceuticals Ltd. Hcv inhibiting sulfonamides

Also Published As

Publication number Publication date
PL2035432T3 (pl) 2012-07-31
AU2007262943B2 (en) 2012-04-12
CN101479275B (zh) 2012-03-07
JP5232776B2 (ja) 2013-07-10
TW200817416A (en) 2008-04-16
EA016387B1 (ru) 2012-04-30
UY30416A1 (es) 2008-01-31
JO2841B1 (en) 2014-09-15
US8202887B2 (en) 2012-06-19
CA2653233A1 (en) 2007-12-27
PE20080342A1 (es) 2008-04-25
EP2035432B1 (en) 2012-02-08
US20090209583A1 (en) 2009-08-20
AU2007262943A1 (en) 2007-12-27
BRPI0713487B1 (pt) 2022-07-26
TWI415851B (zh) 2013-11-21
JP2009541272A (ja) 2009-11-26
NZ573286A (en) 2011-09-30
ATE544769T1 (de) 2012-02-15
KR101419320B1 (ko) 2014-07-14
EA200970052A1 (ru) 2009-04-28
AP2008004679A0 (en) 2008-12-31
CN101479275A (zh) 2009-07-08
IL195381A (en) 2013-01-31
HK1125633A1 (US20060241273A1-20061026-C00026.png) 2009-08-14
AP2069A (en) 2009-12-08
MY146805A (en) 2012-09-28
EP2035432A1 (en) 2009-03-18
PT2035432E (pt) 2012-04-24
BRPI0713487A2 (US20060241273A1-20061026-C00026.png) 2012-11-13
CA2653233C (en) 2015-09-29
KR20090024257A (ko) 2009-03-06
ZA200810350B (en) 2010-05-26
MX2009000160A (es) 2009-01-23
BRPI0713487A8 (pt) 2018-01-02
UA96445C2 (ru) 2011-11-10
WO2007147884A1 (en) 2007-12-27
IL195381A0 (en) 2009-08-03
DK2035432T3 (da) 2012-05-14
SI2035432T1 (sl) 2012-06-29
CL2007001826A1 (es) 2008-01-18
ES2381129T3 (es) 2012-05-23
AR061619A1 (es) 2008-09-10

Similar Documents

Publication Publication Date Title
CY1112971T1 (el) Σουλφοναμιδια 2-(υποκατεστημενο-αμινο)-βενζοθειαζολης ως αναστολεις της πρωτεασης ηiv
ATE544870T1 (de) Profilierung einer rezeptorfamilie
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
EA200802074A1 (ru) Способ получения бисфуранового спирта, соединения, соль, фармацевтическая композиция на ее основе, способ для лечения или профилактики ретровирусных инфекций с ее помощью и способ ингибирования вич протеазы с ее помощью
NO20045152L (no) Ikke-nukleosid-reverstranskriptaseinhibitorer
EA200802209A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
ECSP099044A (es) Compuestos de pirimido fusionados
TR200201187T2 (tr) Ters transkriptazın inhibitörleri olarak benzofenonlar
BRPI0815920A2 (pt) Composto, composição farmacêutica, e, uso do composto.
UY30748A1 (es) Compuesto0s novedosos
BRPI0510665A (pt) 3-(4-heteroarilcicloexilamino) ciclopentano-carboxiamidas como moduladores de receptores de quimiocinas
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
HN2007000437A (es) Compuestos de pirazolina y su uso y composiciones farmaceuticas
UY30048A1 (es) Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
ATE511500T1 (de) Sulfonamide als orexin-antagonisten
EA200602281A1 (ru) Гетероарилсульфоны и сульфонамиды и их терапевтические применения
EA200801476A1 (ru) Замещенные аминофенилсульфонамидные соединения в качестве ингибиторов протеазы вич
BRPI0915878A2 (pt) sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
BRPI0820838B8 (pt) derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso como antagonistas do receptor purinérgico p2x3 e/ou p2x2/3
UY30801A1 (es) Compuestos calciliticos
BR0306927A (pt) Compostos tricìclicos de 2-pirimidona úteis como inibidores de transcriptase reversa de hiv
TW200710091A (en) (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
BR0208987A (pt) Composto tricìclicos úteis como inibidores de transcriptase reserva de hiv
UY30552A1 (es) Combinaciones farmacologiicas en base a derivados sustituidos de la n-(5-{2-[1,1-dimetil-propilamino]-1-hidroxi-metil}-2-hidroxi-fenil)-metansulfonamida y aplicaciones